---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-25-000152"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2025-10-29T23:59:59+00:00"
generated_at: "2026-05-17T01:39:34.588618+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Roche exercises option for Recursion's Microglia Map; $30M fee

## Summary
- Roche exercised option for a first-of-its-kind whole genome map of brain immune cells (Microglia Map) from Recursion.
- Recursion will receive a $30 million Acceptance Fee from Roche under the 2021 Collaboration and License Agreement.
- The Microglia Map is generated by Recursion's platform as part of the ongoing partnership with Roche.

## SEC filing metadata
- accession: 0001601830-25-000152
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2025-10-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183025000152/0001601830-25-000152-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183025000152/rxrx-20251029.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-25-000152
- JSON: https://secwatch.observer/filing/0001601830-25-000152.json
- Plain text: https://secwatch.observer/filing/0001601830-25-000152.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.